Inici › Limfoma de Burkitt › Oklahoma
Assaigs clínics de Limfoma de Burkitt a Oklahoma
7 estudis de Limfoma de Burkitt busquen participants en centres de Oklahoma.
Ciutats de Oklahoma
Text oficial de l'estudi (anglès)
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
- University of Oklahoma Health Sciences Center, Oklahoma City
ReclutantFase 2
366 Days – 46 Years · Tots els sexes · Actualitzat el 2 d’oct. 2026 · NCT06124157Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
- University of Oklahoma Health Sciences Center, Oklahoma City
ReclutantFase 3
Edats de 18 a 39 · Tots els sexes · Actualitzat el 2 d’oct. 2026 · NCT03150693Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- University of Oklahoma Health Sciences Center, Oklahoma City
ReclutantFase 2
Edats de 18 anys en endavant · Tots els sexes · Actualitzat el 29 de set. 2026 · NCT03739814Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
- University of Oklahoma Health Sciences Center, Oklahoma City
ReclutantFase 2
365 Days · Tots els sexes · Actualitzat el 25 de set. 2026 · NCT06317662A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
- University of Oklahoma Health Sciences Center, Oklahoma City
- Saint Francis Children's Hospital, Tulsa
ReclutantFase 2
Edats de 1 a 30 · Tots els sexes · Actualitzat el 1 de set. 2026 · NCT04546399Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- University of Oklahoma Health Sciences Center, Oklahoma City
- Saint Francis Children's Hospital, Tulsa
ReclutantFase 3
365 Days – 25 Years · Tots els sexes · Actualitzat el 25 d’ag. 2026 · NCT03959085Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene
- University of Oklahoma Health Sciences Center, Oklahoma City
ReclutantFase 1/2
Edats de 18 anys en endavant · Tots els sexes · Actualitzat el 31 de jul. 2026 · NCT07069699De ClinicalTrials.gov, dades recuperades el 5 d’oct. 2026. Cada estudi estableix els seus propis criteris d'elegibilitat; l'equip de l'estudi decideix qui hi pot participar.